XRAY Dentsply Sirona Inc

Dentsply Sirona (NASDAQ: XRAY) shares were last at $11.52 in early premarket trading, following an ex-dividend session where the stock traded without the right to its next $0.16 per share dividend, payable on January 9. The dental products maker's stock rose 2.7% on the last regular session (December 26), and analysts anticipate its next earnings report around February 26. Investors are closely watching demand for dental equipment, margin trends, cash flow, and the company's dividend policy for 2026.

Dentsply Sirona (NASDAQ: XRAY) is heading into the end of 2025 with mixed signals for investors, balancing year-end market seasonality, an attractive dividend yield, and a cautious analyst community. Analysts currently have a "Reduce" consensus rating with varying price targets, indicating that sustained improvements are needed for a re-rating. Investors are also monitoring the dividend timeline and an insider's planned share sale, while the stock grapples with past earnings misses and revised guidance.

Analysts maintain a "Reduce" consensus on DENTSPLY SIRONA (NASDAQ: XRAY) as year-end trading approaches, despite the stock closing higher on Friday. The company faces operational headwinds and is implementing a "Return-to-Growth" action plan, which analysts are cautiously monitoring. Key factors for investors include the recent ex-dividend date, technical reference levels, and upcoming earnings expected in February 2026.

This article provides a weekend update on Dentsply Sirona (XRAY) stock, focusing on its dividend, ongoing turnaround plan, and analyst targets as the Nasdaq reopens. It details the company's Q3 2025 financial results, revised full-year outlook, leadership changes, and the conclusion of an SEC investigation. The piece also offers insights for investors on what to monitor in the coming trading sessions regarding the company's "Return-to-Growth" strategy and dividend timeline.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has received a consensus "Reduce" rating from fifteen analysts, with an average 1-year target price of $15.15. The company recently reported Q3 EPS of $0.37, missing expectations of $0.45, and set its FY2025 EPS guidance at $1.60 against analyst forecasts of $1.84. Insider activity includes a director selling 82,200 shares, and institutions collectively own 95.70% of the stock.

DENTSPLY SIRONA (XRAY) disclosed $50,000 in lobbying efforts for Q4 2025, focusing on dental services, competitive bidding, and international trade policies. Insider trading activity for XRAY shows balanced purchases and sales, while institutional investors have made significant adjustments to their holdings. Analysts have issued "Buy" and "Outperform" ratings, with a median price target of $12.5.